Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant - Trial NCT05889585
Access comprehensive clinical trial information for NCT05889585 through Pure Global AI's free database. This phase not specified trial is sponsored by Gustave Roussy, Cancer Campus, Grand Paris and is currently Recruiting. The study focuses on Germ Cell Tumor. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Gustave Roussy, Cancer Campus, Grand Paris
Timeline & Enrollment
N/A
May 31, 2023
May 01, 2024
Primary Outcome
Compare the quality of life between the three groups measured with the EORTC-QLQ C-30 questionnaire.
Summary
Intensified chemotherapy is an effective treatment in 30-70% of patients with refractory germ
 cell tumor. Since most cases are diagnosed before the age of 40, survivors can expect to live
 another 30 to 50 years after being successfully treated. Long-term side effects and physical
 and emotional consequences can therefore have a significant impact on daily life. To date, no
 data of this type is available in France. This study will help clinicians better understand
 the long-term consequences for relapsed patients receiving high-dose chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05889585
Non-Device Trial